Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol Aug 28, 2014 09:15AM
Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA Aug 28, 2014 09:00AM
FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure Aug 27, 2014 09:15AM
Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis Aug 18, 2014 05:17PM
Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates Aug 13, 2014 04:12PM


Aug 13, 2014 04:01PM Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma
Aug 4, 2014 07:30AM Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint
Jul 30, 2014 10:29AM Top 10 Trending Stocks for 07/30: Twitter (TWTR), Amgen (AMGN), Regeneron (REGN), and More...
Jul 30, 2014 09:32AM Pre-Open Stock Movers 7/30: (GFIG) (TWTR) (NQ) Higher; (NTRI) (BWLD) (DWA) Lower (more...)
Jul 29, 2014 06:10PM After-Hours Stock Movers 7/29: (TWTR) (ZLTQ) (X) Higher; (NTRI) (BWLD) (DWA) Lower (more...)
Jul 29, 2014 05:37PM Market Wrap: Home Prices Gain at Slower Pace; Twitter Soars in Q2; Ford Opts for Apple
Jul 29, 2014 04:37PM Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37
Jul 28, 2014 05:11PM Trading Radar for 07/29: Pfizer (PFE), Marriott (MAR), UPS (UPS), Anadarko (APC), Ballard Power (BLDP) Report
Jul 25, 2014 04:00PM Amgen Announces 2014 Third Quarter Dividend
Jul 25, 2014 02:30AM Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
Jul 24, 2014 04:00PM Amgen Announces Webcast of 2014 Second Quarter Financial Results
Jul 17, 2014 04:01PM Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
Jul 1, 2014 08:09AM Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia
Jun 16, 2014 04:03PM Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
Jun 11, 2014 05:00PM Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine
Jun 9, 2014 04:15PM Amgen Appoints David W. Meline Executive Vice President and Chief Financial Officer
Jun 6, 2014 04:15PM Amgen To Present At The Goldman Sachs Global Healthcare Conference